Melissa P. Upton, MD
Department of Pathology, University of Washington, Seattle

Faculty/Authors
Sun Min Lee, MD 
Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, South Korea; Department of Laboratory Medicine; and Research Institute for Convergence of Biomedical Science and Technology  

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online Educational Activity and Post-Test

Physician Competencies: Medical knowledge, patient care, practice-based learning

Eligibility for CME/CMLE credit: Max three attempts. You will have a maximum of three attempts to meet the following criteria:

• Module ≥80% = CME credit
• Module <80% = No CME credit, after a maximum of three attempts

Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME or SAMs CME credit.)

Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Course to view an overview of the modules in this course.
3. Click Access to begin the course.
4. Review the Educational Activity.
5. Complete and submit the Post-Test. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
6. Submit the course Evaluation to register your credit.

Faculty Disclosures​
The Journal CME editor and faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date: 7/13/2022
Review Date:
Expiration Date: 7/13/2025

• List settings and situations in which cell-free DNA (cfDNA) might be used instead of tumor tissue for evaluation of epidermal growth factor receptor (EGFR) mutations. 

• Discuss the utility of Epidermal growth factor receptor mutation analysis in patients with non-small cell lung cancer, and list the common mutations associated with resistance to tyrosine kinase inhibitors. 

• Describe technical aspects of cfDNA sample centrifugation that affect detection of EFGR mutations.